Funding
Seed · Biotech

Vitroscope raises $5 million seed round for live-tissue research

Cerberus Ventures and YZR Capital co-led the equity financing, alongside separate non-dilutive support.

By RoundOS Funding desk

Vitroscope has raised a $5 million seed round co-led by Cerberus Ventures and YZR Capital. Arcas Ventures, Golden Egg Check, Devico Invest and angels Carles Reina, Fàtima Godall and Oskari Pétas also participated.

The Norwegian company announced a further $2 million in non-dilutive funding from the Research Council of Norway. The package will support the rollout of vitro.alive and validation of vitro.scale, which is designed to run more tissue experiments in parallel.

Use of funds

Commercial rollout of vitro.alive

Validation of vitro.scale

Funding history

Seed · This round$5M

Sources

  1. businesswire.com
  2. Vitroscope financing announcementtech.eu · Nov 3, 2026

Similar rounds

All Biotech rounds →
GPN Vaccines

GPN Vaccines develops bacterial vaccines designed to protect against a broader range of strains than conventional serotype-specific vaccines.

$10MPrivate placement · Nov 2, 2026
ALLOX

ALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.

$10.5MSeed · Oct 29, 2026
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing · Oct 29, 2026
BioGeometry

BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.

UndisclosedSeries A+ · Oct 28, 2026

Related